{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:56:08Z","timestamp":1792112168148,"version":"4.4.0"},"reference-count":119,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"8","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2025,8,27]]},"DOI":"10.1167\/tvst.14.8.37","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:30:46Z","timestamp":1756301446000},"page":"37","source":"Crossref","is-referenced-by-count":7,"title":["Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium"],"prefix":"10.1167","volume":"14","author":[{"given":"Debra A.","family":"Thompson","sequence":"first","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Thiran","family":"Jayasundera","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Alekseev","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin R.","family":"Ali","sequence":"additional","affiliation":[{"name":"Centre for Gene Therapy and Regenerative Medicine, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Amato","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS Bambino Ges\u00f9 Children's Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim Y.","family":"Arshavsky","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle S.","family":"Audo","sequence":"additional","affiliation":[{"name":"Institut de la Vision, Sorbonne Universit\u00e9, INSERM, CNRS, Paris, France"},{"name":"Centre Hospitalier National D'Ophtalmologie des Quinze Vingts, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Auricchio","sequence":"additional","affiliation":[{"name":"Telethon Institute of Genetics and Medicine, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W. B.","family":"Bainbridge","sequence":"additional","affiliation":[{"name":"Institute of Ophthalmology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Banin","sequence":"additional","affiliation":[{"name":"Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Ein-Karem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagri G.","family":"Besirli","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Birch","sequence":"additional","affiliation":[{"name":"Retina Foundation of the Southwest, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari E.","family":"Branham","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur V.","family":"Cideciyan","sequence":"additional","affiliation":[{"name":"Center for Hereditary Retinal Degenerations, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Daiger","sequence":"additional","affiliation":[{"name":"Human Genetics Center, Epidemiology Department, School of Public Health, University of Texas Health Science Center-Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacque L.","family":"Duncan","sequence":"additional","affiliation":[{"name":"Wayne and Gladys Valley Center for Vision, Department of Ophthalmology, University of California-San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail T.","family":"Fahim","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Flannery","sequence":"additional","affiliation":[{"name":"Helen Wills Neuroscience Institute, University of California-Berkeley, Berkeley, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gattegna","sequence":"additional","affiliation":[{"name":"Retina Service, Israelitic Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Heckenlively","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"H\u00e9on","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Iannaccone","sequence":"additional","affiliation":[{"name":"Cell and Gene Therapy, Biopharma and Ophthalmology Division, Astellas Pharma US, Northbrook, IL, USA"},{"name":"Kittner Eye Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naheed W.","family":"Khan","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Khateb","sequence":"additional","affiliation":[{"name":"Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Ein-Karem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Klassen","sequence":"additional","affiliation":[{"name":"Gavin Herbert Eye Institute, Stem Cell Research Center, University of California-Irvine, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart P.","family":"Leroy","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Center for Medical Genetics, Ghent University Hospital & Ghent University, Ghent, Belgium"},{"name":"Division of Ophthalmology and Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Marangoni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Health Sciences, Ophthalmology Clinic, University of Trieste, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Michaelides","sequence":"additional","affiliation":[{"name":"Institute of Ophthalmology, University College London, London, UK"},{"name":"Moorfields Eye Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Musch","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Pennesi","sequence":"additional","affiliation":[{"name":"Retina Foundation of the Southwest, Dallas, TX, USA"},{"name":"Casey Eye Institute, Oregon Health Science Center, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon M.","family":"Petersen-Jones","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Pierce","sequence":"additional","affiliation":[{"name":"Ocular Genomics Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh C.","family":"Rao","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[{"name":"Institut de la Vision, Sorbonne Universit\u00e9, INSERM, CNRS, Paris, France"},{"name":"Centre Hospitalier National D'Ophtalmologie des Quinze Vingts, Paris, France"},{"name":"Fondation Ophtalmologique, Rothschild, Paris, France"},{"name":"UPMC Vision Institute, Department of Ophthalmology, University of Pittsburg School of Medicine, Pittsburg, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Sieving","sequence":"additional","affiliation":[{"name":"Center for Ocular Regenerative Therapy, Department of Ophthalmology, University of California-Davis School of Medicine, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Strettoi","sequence":"additional","affiliation":[{"name":"CNR Neuroscience Institute, Area della Ricerca, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron R.","family":"Strong","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Wubben","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yang","sequence":"additional","affiliation":[{"name":"Casey Eye Institute, Oregon Health Science Center, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Zacks","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Monaciano Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","first-page":"53","article-title":"Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy","volume":"60","year":"2018","journal-title":"Med Lett Drugs Ther"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"101244","DOI":"10.1016\/j.preteyeres.2024.101244","article-title":"Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes","volume":"100","author":"Georgiou","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"a041728","DOI":"10.1101\/cshperspect.a041728","article-title":"Retinal disorders","volume":"14","author":"Sahel","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.3390\/jcm13185512","article-title":"Update on clinical trial endpoints in gene therapy trials for inherited retinal diseases","volume":"13","author":"Igoe","year":"2024","journal-title":"J Clin Med"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/tvst.13.12.28","article-title":"Inherited retinal degenerations and non-neovascular age-related macular degeneration: progress and unmet needs","volume":"13","author":"Duncan","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"e2038","DOI":"10.1002\/mgg3.2038","article-title":"Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence","volume":"10","author":"Kolesnikova","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"Reichel","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1167\/iovs.14-16049","article-title":"Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium","volume":"56","author":"Thompson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.9.7.2","article-title":"Advancing clinical trials for inherited retinal diseases: recommendations from the Second Monaciano Symposium","volume":"9","author":"Thompson","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/tvst.12.6.5","article-title":"Overcoming the challenges to clinical development of X-linked retinitis pigmentosa therapies: proceedings of an expert panel","volume":"12","author":"Birch","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0140-6736(24)01447-8","article-title":"Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1\/2, multicentre, open-label, unilateral dose escalation study","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1038\/s41467-024-51575-4","article-title":"Interim safety and efficacy of gene therapy for RLBP1-associated retinal dystrophy: a phase 1\/2 trial","volume":"15","author":"Kvanta","year":"2024","journal-title":"Nat Commun"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ajo.2024.05.034","article-title":"Phase 1\/2 AAV5-hRKp.RPGR (botaretigene sparoparvovec) gene therapy: safety and efficacy in RPGR-associated X-linked retinitis pigmentosa","volume":"267","author":"Michaelides","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ajo.2024.11.021","article-title":"Subretinal gene therapy drug AGTC-501 for XLRP phase 1\/2 multicenter study (HORIZON): 24-month safety and efficacy results: subretinal gene therapy AGTC-501 for XLRP Ph 1\/2 24M results","volume":"271","author":"Yang","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I\/IIa Trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol Ther"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1136\/bjo-2022-321903","article-title":"Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes","volume":"107","author":"Daich Varela","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms25063391","article-title":"A Precision therapy approach for retinitis pigmentosa 11 using splice-switching antisense oligonucleotides to restore the open reading frame of PRPF31","volume":"25","author":"Grainok","year":"2024","journal-title":"Int J Mol Sci"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat Med"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"101873","DOI":"10.1016\/j.ajoc.2023.101873","article-title":"Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP290-LCA: Replication in two eyes","volume":"32","author":"Cideciyan","year":"2023","journal-title":"Am J Ophthalmol Case Rep"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.omtn.2023.05.020","article-title":"A protein domain-oriented approach to expand the opportunities of therapeutic exon skipping for USH2A-associated retinitis pigmentosa","volume":"32","author":"Schellens","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"102374","DOI":"10.1016\/j.omtn.2024.102374","article-title":"Exploring non-coding variants and evaluation of antisense oligonucleotides for splicing redirection in Usher syndrome","volume":"35","author":"Garcia-Bohorquez","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N Engl J Med"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1089\/hum.2012.008","article-title":"Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat((R)), for age-related macular degeneration","volume":"23","author":"Binley","year":"2012","journal-title":"Hum Gene Ther"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajo.2022.02.013","article-title":"Three- year safety results of SAR422459 (EIAV-ABCA4) gene therapy in patients with ABCA4-associated Stargardt disease: an open-label dose-escalation phase I\/IIa clinical trial, cohorts 1\u20135","volume":"240","author":"Parker","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.omtm.2023.02.002","article-title":"Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B","volume":"28","author":"Ferla","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"102311","DOI":"10.1016\/j.omtn.2024.102311","article-title":"RNA exon editing: splicing the way to treat human diseases","volume":"35","author":"Doi","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"105274","DOI":"10.1016\/j.isci.2022.105274","article-title":"Night vision restored in days after decades of congenital blindness","volume":"25","author":"Jacobson","year":"2022","journal-title":"iScience"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"100133","DOI":"10.1016\/j.xops.2022.100133","article-title":"Restoration of cone sensitivity to individuals with congenital photoreceptor blindness within the phase 1\/2 Sepofarsen trial","volume":"2","author":"Cideciyan","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/opo.12775","article-title":"Low luminance visual acuity as a clinical measure and clinical trial outcome measure: a scoping review","volume":"41","author":"Wood","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"key":"bib33","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/biom13101484","article-title":"Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center","volume":"13","author":"Kiraly","year":"2023","journal-title":"Biomolecules"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.oret.2023.08.017","article-title":"Classification and growth rate of chorioretinal atrophy after voretigene neparvovec-Rzyl for RPE65-mediated retinal degeneration","volume":"8","author":"Bommakanti","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"bib37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ophtha.2023.09.006","article-title":"Single center experience with voretigene neparvovec gene augmentation therapy in RPE65 mutation-associated inherited retinal degeneration in a clinical setting","volume":"131","author":"Lorenz","year":"2024","journal-title":"Ophthalmology"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/tvst.13.6.11","article-title":"Perimacular atrophy following voretigene neparvovec-rzyl treatment in the setting of previous contralateral eye treatment with a different viral vector","volume":"13","author":"Ku","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-025-03691-8","article-title":"Voretigene neparvovec in RPE65-related inherited retinal dystrophy: the 1-year real-world study LIGHT","volume":"39","author":"Audo","year":"2025","journal-title":"Eye (Lond)"},{"key":"bib41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archophthalmol.2010.46","article-title":"How strong is the evidence that nutritional supplements slow the progression of retinitis pigmentosa?","volume":"128","author":"Massof","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":". Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaophthalmol.2018.1171","article-title":"Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa: a randomized phase 2 multicenter placebo-controlled clinical trial","volume":"136","author":"Birch","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/ijms23031138","article-title":"Retinal plasticity","volume":"23","author":"Strettoi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"26ps16","DOI":"10.1126\/scitranslmed.3000866","article-title":"Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling","volume":"2","author":"Leveillard","year":"2010","journal-title":"Sci Transl Med"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/hmg\/ddl185","article-title":"In vivo function of the orphan nuclear receptor NR2E3 in establishing photoreceptor identity during mammalian retinal development","volume":"15","author":"Cheng","year":"2006","journal-title":"Hum Mol Genet"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuron.2006.02.026","article-title":"Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration","volume":"50","author":"Bi","year":"2006","journal-title":"Neuron"},{"key":"bib48","first-page":"041412","article-title":"Restoring vision in mice with retinal degeneration using multicharacteristic opsin","volume":"4","author":"Wright","year":"2017","journal-title":"Neurophotonics"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s42003-020-01594-w","article-title":"Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates","volume":"4","author":"Gauvain","year":"2021","journal-title":"Commun Biol"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.1111\/jcmm.16823","article-title":"Biodistribution of adeno-associated virus type 2 carrying multi-characteristic opsin in dogs following intravitreal injection","volume":"25","author":"Tchedre","year":"2021","journal-title":"J Cell Mol Med"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"1177838","DOI":"10.3389\/fcell.2023.1177838","article-title":"Gene-agnostic approaches to treating inherited retinal degenerations","volume":"11","author":"Chew","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat Med"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/tvst.13.10.25","article-title":"Multi-characteristic opsin therapy to functionalize retina, attenuate retinal degeneration, and restore vision in mouse models of retinitis pigmentosa","volume":"13","author":"Batabyal","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/jop.2024.0084","article-title":"Efficacy of intravitreal multi-characteristic opsin (MCO-010) optogenetic gene therapy in a mouse model of Leber congenital amaurosis","volume":"40","author":"Dibas","year":"2024","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib55","first-page":"179","article-title":"Investigations of antiretinal antibodies in pigmentary retinopathy and other retinal degenerations","volume":"94","author":"Heckenlively","year":"1996","journal-title":"Trans Am Ophthalmol Soc"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"10177","DOI":"10.1096\/fj.201900414R","article-title":"Rescuing cones and daylight vision in retinitis pigmentosa mice","volume":"33","author":"Guadagni","year":"2019","journal-title":"FASEB J"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-vision-121219-081730","article-title":"Microglia activation and inflammation during the death of mammalian photoreceptors","volume":"6","author":"Karlen","year":"2020","journal-title":"Annu Rev Vis Sci"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/ijms23010386","article-title":"The role of inflammation in retinal neurodegeneration and degenerative diseases","volume":"23","author":"Kaur","year":"2021","journal-title":"Int J Mol Sci"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"1059947","DOI":"10.3389\/fimmu.2022.1059947","article-title":"Neuroinflammation in retinitis pigmentosa: therapies targeting the innate immune system","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"a041305","DOI":"10.1101\/cshperspect.a041305","article-title":"Immunology of retinitis pigmentosa and gene therapy-associated uveitis","volume":"14","author":"Yang","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajoint.2024.100085","article-title":"Intravitreal dexamethasone implant concomitant to cataract surgery in retinitis pigmentosa: potential retinal preservation effect","volume":"1","author":"Savastano","year":"2024","journal-title":"AJO International"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"5698931","DOI":"10.1155\/2016\/5698931","article-title":"Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?","volume":"2016","author":"Biswas","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1172\/JCI132990","article-title":"Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial","volume":"130","author":"Campochiaro","year":"2020","journal-title":"J Clin Invest"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.3390\/ijms25158060","article-title":"Amelioration of photoreceptor degeneration by intravitreal transplantation of retinal progenitor cells in rats","volume":"25","author":"Yang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"eadl3576","DOI":"10.1126\/sciadv.adl3576","article-title":"Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes","volume":"10","author":"Shen","year":"2024","journal-title":"Sci Adv"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/978-3-319-17121-0","article-title":"My Retina Tracker: an on-line international registry for people affected with inherited orphan retinal degenerative diseases and their genetic relatives - a new resource","volume":"854","author":"Fisher","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamaophthalmol.2021.0004","article-title":"Association of no-cost genetic testing program implementation and patient characteristics with access to genetic testing for inherited retinal degenerations","volume":"139","author":"Zhao","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"bib69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/tvst.13.10.15","article-title":"Endpoints and design for clinical trials in USH2A-related retinal degeneration: results and recommendations from the RUSH2A Natural History study","volume":"13","author":"Maguire","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"bib70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ophtha.2015.12.009","article-title":"The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies: design and baseline characteristics: ProgStar report no. 1","volume":"123","author":"Strauss","year":"2016","journal-title":"Ophthalmology"},{"key":"bib71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/IIO.0000000000000380","article-title":"Choosing outcome measures and assessing efficacy of therapeutic interventions in inherited retinal diseases: the importance of natural history studies","volume":"61","author":"Iannaccone","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"bib72","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jcjo.2024.12.006","article-title":"Insights into the effects of subretinal voretigene neparvovec-rzyl in RPE65-associated Leber congenital amaurosis: an 18-month report","volume":"60","author":"Tayyib","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"bib73","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/jmedgenet-2013-101558","article-title":"Comprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencing","volume":"50","author":"Wang","year":"2013","journal-title":"J Med Genet"},{"key":"bib74","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00439-013-1381-5","article-title":"Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-phenotype correlation and clinical refinements","volume":"133","author":"Wang","year":"2014","journal-title":"Hum Genet"},{"key":"bib75","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/gim.2014.172","article-title":"Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencing","volume":"17","author":"Consugar","year":"2015","journal-title":"Genet Med"},{"key":"bib76","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.ophtha.2017.04.008","article-title":"Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease","volume":"124","author":"Stone","year":"2017","journal-title":"Ophthalmology"},{"key":"bib77","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3390\/ijms23020995","article-title":"Clinical and genetic re-evaluation of inherited retinal degeneration pedigrees following initial negative findings on panel-based next generation sequencing","volume":"23","author":"Stephenson","year":"2022","journal-title":"Int J Mol Sci"},{"key":"bib78","first-page":"203","article-title":"Identification of numerous novel disease-causing variants in patients with inherited retinal diseases, combining careful clinical-functional phenotyping with systematic, broad NGS panel-based genotyping","volume":"28","author":"Gupta","year":"2022","journal-title":"Mol Vis"},{"key":"bib80","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1097\/IAE.0000000000004155","article-title":"Diagnostic yield of an inherited retinal disease gene panel in retinopathy of unknown origin","volume":"44","author":"Abramowicz","year":"2024","journal-title":"Retina"},{"key":"bib81","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1001\/jamaophthalmol.2024.4696","article-title":"Racial disparities in genetic detection rates for inherited retinal diseases","volume":"142","author":"Abuzaitoun","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"bib82","doi-asserted-by":"publisher","first-page":"a041301","DOI":"10.1101\/cshperspect.a041301","article-title":"Current status of clinical trials design and outcomes in retinal gene therapy","volume":"14","author":"Rosin","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"bib83","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy","volume":"123","author":"Weleber","year":"2016","journal-title":"Ophthalmology"},{"key":"bib84","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/biomedicines11010103","article-title":"Gene therapy with voretigene neparvovec improves vision and partially restores electrophysiological function in pre-school children with Leber congenital amaurosis","volume":"11","author":"Gerhardt","year":"2022","journal-title":"Biomedicines"},{"key":"bib85","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10633-024-09987-6","article-title":"Partial rescue of the full-field electroretinogram in patients with RPE65-related retinal dystrophy following gene augmentation therapy with voretigene neparvovec-rzyl","volume":"149","author":"Amato","year":"2024","journal-title":"Doc Ophthalmol"},{"key":"bib86","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"key":"bib87","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"key":"bib88","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N Engl J Med"},{"key":"bib89","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"bib90","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000526317","article-title":"Gene therapy for inherited retinal disease: long-term durability of effect","volume":"66","author":"Leroy","year":"2023","journal-title":"Ophthalmic Res"},{"key":"bib91","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/tvst.12.1.28","article-title":"Optimization and validation of a virtual reality orientation and mobility test for inherited retinal degenerations","volume":"12","author":"Bennett","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"bib92","doi-asserted-by":"publisher","first-page":"1251935","DOI":"10.3389\/fnins.2023.1251935","article-title":"Measuring visually guided motor performance in ultra low vision using virtual reality","volume":"17","author":"Kartha","year":"2023","journal-title":"Front Neurosci"},{"key":"bib93","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2023.06.028","article-title":"Development and validation of a novel mobility test for rod-cone dystrophies: from reality to virtual reality","volume":"258","author":"Authie","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"bib96","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ajo.2020.08.032","article-title":"The Michigan Retinal Degeneration Questionnaire: a patient-reported outcome instrument for inherited retinal degenerations","volume":"222","author":"Lacy","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"bib97","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2022.11.021","article-title":"Construct validity of inherited retinal disease-specific patient-reported outcome measures","volume":"248","author":"Jayasundera","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"bib98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.65.6.5","article-title":"Self-Reported functional vision in USH2A-associated retinal degeneration as measured by the Michigan Retinal Degeneration Questionnaire","volume":"65","author":"Parekh","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib99","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/13816810.2020.1776337","article-title":"Content generation for patient-reported outcome measures for retinal degeneration therapeutic trials","volume":"41","author":"Lacy","year":"2020","journal-title":"Ophthalmic Genet"},{"key":"bib100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13816810.2020.1731836","article-title":"Patient-reported outcome measures in inherited retinal degeneration gene therapy trials","volume":"41","author":"Lacy","year":"2020","journal-title":"Ophthalmic Genet"},{"key":"bib101","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s40123-023-00670-8","article-title":"Psychometric validation of the ViSIO-PRO and ViSIO-ObsRO in retinitis pigmentosa and Leber congenital amaurosis","volume":"12","author":"Fischer","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"bib102","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/13816810.2023.2208211","article-title":"Positive feedback loop between vision-related anxiety and self-reported visual difficulty","volume":"44","author":"Popova","year":"2023","journal-title":"Ophthalmic Genet"},{"key":"bib103","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jamaophthalmol.2013.4160","article-title":"Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa","volume":"131","author":"Birch","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"bib104","doi-asserted-by":"publisher","first-page":"a041285","DOI":"10.1101\/cshperspect.a041285","article-title":"Adaptive optics imaging of inherited retinal disease","volume":"13","author":"Duncan","year":"2023","journal-title":"Cold Spring Harb Perspect Med"},{"key":"bib105","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMe2405256","article-title":"Success in sight for gene editing","volume":"390","author":"Bainbridge","year":"2024","journal-title":"N Engl J Med"},{"key":"bib106","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1016\/j.jcjo.2024.12.013","article-title":"\u201cBlindness\u201d is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases","volume":"60","author":"Parameswarappa","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"bib107","doi-asserted-by":"publisher","first-page":"104095","DOI":"10.1016\/j.drudis.2024.104095","article-title":"Therapies for inherited retinal dystrophies: what is enough?","volume":"29","author":"Leroy","year":"2024","journal-title":"Drug Discov Today"},{"key":"bib108","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/13816810.2022.2050765","article-title":"Adherence and satisfaction in Argus II prosthesis users: a self determination theory model","volume":"43","author":"Khan","year":"2022","journal-title":"Ophthalmic Genet"},{"key":"bib109","doi-asserted-by":"publisher","first-page":"a041660","DOI":"10.1101\/cshperspect.a041660","article-title":"Optogenetic vision restoration","volume":"14","author":"Busskamp","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"bib110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10633-023-09962-7","article-title":"ISCEV and IPS guideline for the full-field stimulus test (FST)","volume":"148","author":"Jolly","year":"2024","journal-title":"Doc Ophthalmol"},{"key":"bib111","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.08.009","article-title":"Challenges of cost-effectiveness analyses of novel therapeutics for inherited retinal diseases","volume":"235","author":"Jayasundera","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"bib112","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.2147\/OPTH.S313719","article-title":"The Impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective","volume":"15","author":"Gong","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"bib113","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/0145482X0910300303","article-title":"Family functioning and low vision: a systematic review","volume":"103","author":"Bambara","year":"2009","journal-title":"J Vis Impair Blind"},{"key":"bib114","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5694\/mja2.51997","article-title":"The health care and societal costs of inherited retinal diseases in Australia: a microsimulation modelling study","volume":"219","author":"Schofield","year":"2023","journal-title":"Med J Aust"},{"key":"bib115","doi-asserted-by":"publisher","first-page":"11642","DOI":"10.1038\/s41598-024-62558-2","article-title":"Theoretical prediction of broadband ambient light optogenetic vision restoration with ChRmine and its mutants","volume":"14","author":"Bansal","year":"2024","journal-title":"Sci Rep"},{"key":"bib117","doi-asserted-by":"publisher","first-page":"N51","DOI":"10.1088\/0967-3334\/28\/8\/N02","article-title":"Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials","volume":"28","author":"Roman","year":"2007","journal-title":"Physiol Meas"},{"key":"bib2","author":"Foundation Fighting Blindness","year":"2024"},{"key":"bib14","article-title":"EyeDNA Therapeutics announces positive 24-month data presented at ARVO from ongoing phase I\/II trial ofHORA-PDE6b gene therapy in patients with retinitis pigmentosa caused by bi-allelic mutations in PDE6b","author":"Coave Therapeutics","year":"2024"},{"key":"bib64","author":"Foundation Fighting Blindness","year":"2024"},{"key":"bib79","author":"RetNet"},{"key":"bib94","author":"Foundation Fighting Blindness","year":"2025"},{"key":"bib95","author":"US Food and Drug AdministrationFDA-2006-D-0362","year":"2006"},{"key":"bib116","author":"US Food and Drug Administration FDA-2016-D-4460","year":"2016"},{"key":"bib118","author":"National Cancer Institute"},{"key":"bib119","author":"Foundation Fighting Blindness Clinical Consortium","year":"2024"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2810738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:30:49Z","timestamp":1756301449000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2810738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":119,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.14.8.37","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}